Accueil > Actualité
Actualite financiere : Actualite bourse

J&J: eye gene therapy shows encouraging results

( - Johnson & Johnson's pharmaceutical unit Janssen said that its gene therapy has showed promising results in an early-stage clinical trial on patients with inherited retinal disease X-linked retinitis pigmentosa (XLRP).

According to six-month data from an ongoing Phase 1/2 trial, low and intermediate doses of the experimental product were generally well-tolerated and resulted in a significant improvement in vision.

In patients with XLRP, the photoreceptors in the eye - which are responsible for converting light into signals that are sent to the brain - function poorly, leading to degeneration of the retina and blindness.

There are currently no approved treatments for this condition.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.